414 related articles for article (PubMed ID: 34686069)
1. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Expert Opin Pharmacother; 2022 Jan; 23(1):19-28. PubMed ID: 34686069
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
3. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
5. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
6. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
[TBL] [Abstract][Full Text] [Related]
7. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.
Luo X; Li G; Yang H; Chen L; Gao Y; Cong J; Luo H; Zhang W
BMC Nephrol; 2024 Feb; 25(1):47. PubMed ID: 38311719
[TBL] [Abstract][Full Text] [Related]
8. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
9. Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
[TBL] [Abstract][Full Text] [Related]
10. Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
Grzeszczak W; Szczyra D; Śnit M
Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567688
[TBL] [Abstract][Full Text] [Related]
11. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
[TBL] [Abstract][Full Text] [Related]
12. Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
Mata Lorenzo M; Ali M; Mealing S; Moss J
J Med Econ; 2023; 26(1):1250-1260. PubMed ID: 37752891
[TBL] [Abstract][Full Text] [Related]
13. Roxadustat: Do we know all the answers?
Li QY; Xiong QW; Yao X; Liu F; Tang X; Fu H; Tong T; Mao J; Peng WX
Biomol Biomed; 2023 May; 23(3):354-363. PubMed ID: 36724056
[TBL] [Abstract][Full Text] [Related]
14. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
[TBL] [Abstract][Full Text] [Related]
15. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
[TBL] [Abstract][Full Text] [Related]
16. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
Song J; Chen X; Zhou L; Yu W; Liu H; Yuan F
J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
[TBL] [Abstract][Full Text] [Related]
17. Roxadustat for Patients with Posttransplant Anemia: A Narrative Review.
Tang X; Liu F; Li Q; Mao J
Kidney Dis (Basel); 2024 Feb; 10(1):32-38. PubMed ID: 38322628
[TBL] [Abstract][Full Text] [Related]
18. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Akizawa T; Otsuka T; Reusch M; Ueno M
Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
[TBL] [Abstract][Full Text] [Related]
19. [Roxadustat (Evrenzo
Ugawa T; Ashizaki M; Murata A; Majikawa Y
Nihon Yakurigaku Zasshi; 2021; 156(3):187-197. PubMed ID: 33952849
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]